Letter: Herpes fight without funding
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Your report "Doctors alarmed as herpes returns with a vengeance" (2 February) reflects our own concern. This infection's propensity to become latent and recur ensures that, unlike other sexually transmitted diseases, the pool of patients with the disease can only increase progressively as patients who have established recurrent disease remain potential sources of infection during herpetic recurrences and, to a lesser extent, between recurrences.
There appears to be no real commitment by the Government or Medical Research Council to prevent this infection by supporting vaccine research. In our own centre we have been researching an inactivated herpes simplex vaccine which in open trial over 15 years appears to offer protection against contraction of the disease. American trials indicate its therapeutic efficacy, without one recorded adverse effect in vaccinated patients.
We cannot obtain the modest funding from public or private sources that would allow evaluation of this vaccine by formal clinical trial, thereby ensuring a potentially useful vaccine does not fall by the wayside. Our experience is reflected in many other vaccine research centres.
Gordon R B Skinner
University of Birmingham
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments